Biotechnology - Atripla

Filter

Current filters:

Atripla

Popular Filters

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Gilead's Stribild to reinforce HIV/AIDS revenues as key patents expire

06-11-2012

US biotech firm Gilead Science's (Nasdaq: GILD) combination drug Stribild (elvitegravir 150mg/cobicistat…

Anti-viralsAtriplaBiotechnologyBristol-Myers SquibbGilead SciencesMarkets & MarketingPatentsReyatazStribildSustiva

Gilead's Quad non-inferior to Atripla for HIV; Truvada objections

08-03-2012

US biotech firm Gilead Sciences (Nasdaq: GILD) yesterday announced full Phase III clinical trial results…

Anti-viralsAtriplaBiotechnologyGilead SciencesNorth AmericaQuadRegulationResearchTruvada

Back to top